A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability and PK of Single Ascending Dose (Part 1) and an Open-label Assessment of Effect of Food on the PK (Part 2).

Trial Profile

A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability and PK of Single Ascending Dose (Part 1) and an Open-label Assessment of Effect of Food on the PK (Part 2).

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs AZD 5213 (Primary)
  • Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Planned End Date changed from 1 Aug 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 10 Jun 2010 Actual end date changed from 1 Jun 20010 to 1 May 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top